Literature DB >> 6160109

Interferon in experimental viral infections in mice: tissue interferon levels resulting from the virus infection and from exogenous interferon therapy.

H Heremans, A Billiau, P De Somer.   

Abstract

In mice given single intraperitoneal doses of interferon, serum interferon levels peaked at 1 h postinjection and were reduced to zero at about 8 h. The interferon concentrations in spleen, liver, and lungs were about 100-fold higher than could be expected from the amount of serum contained in these organs. In the brain only low levels of antiviral activity were detected. In mice infected intraperitoneally with Mengo virus, viral replication in the brain occurred around day 4 and was accompanied by the appearance of large amounts of interferon (approximately 10(3.25) U/g). This was preceded, however, by viral replication in the spleen and by the appearance of modest amounts of interferon in spleen and serum. In these mice protection could be obtained with relatively small doses of interferon, provided protection could be obtained with relatively small doses of interferon, provided they were given before the time of maximal levels of endogenous serum interferon. In mice infected intranasally with vesicular stomatitis virus, virus replication in the brain started within 24 to 48 h and increased with time; also, small amounts of interferon (10(2) to 10(2.5) U/g) were already detectable on days 1 and 2. The major peak of virus replication in the brain occurred on days 5 to 6 and was accompanied by the appearance of large amounts of interferon (approximately 10(3.25) U/g). In this model early treatment with interferon also provided protection, but only if given in larger doses than in the Mengo virus system. Athymic (nu/nu) mice developed a chronic systemic infection when inoculated with a demotropic strain of vaccinia virus. No interferon was detected in sera, livers, spleens, or lungs of these animals; some mice had low levels of interferon-like antiviral activity in the brain, but no attempt was made to characterize this material. Daily administration of large doses of interferon failed to exert an effect on the development of this chronic disease. Yet, normal (NMRI) mice were protected against acute infection with dermotropic or neurotropic strains of vaccinia virus, and athymic mice were partially protected against acute lethal infection with neurotropic vaccinia virus.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6160109      PMCID: PMC551342          DOI: 10.1128/iai.30.2.513-522.1980

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  19 in total

1.  Efficacy of exogenous interferon treatment initiated after onset of multiplication of vesicular stomatitis virus in the brains of mice.

Authors:  I Gresser; M G Tovey; C Bourali-Maury
Journal:  J Gen Virol       Date:  1975-06       Impact factor: 3.891

2.  Recovery of cell-bound interferon.

Authors:  W E Stewart; E De Clercq; P De Somer
Journal:  J Virol       Date:  1972-10       Impact factor: 5.103

3.  Protective effect of interferon and polyacrylic acid in newborn mice infected with a lethal dose of vesicular stomatitis virus.

Authors:  E De Clercq; P De Somer
Journal:  Life Sci       Date:  1968-09-01       Impact factor: 5.037

4.  A comparison of the efficacy of endogenous, exogenous, and combined endogenous-exogenous interferon in the treatment of mice infected with encephalomyocarditis virus.

Authors:  I Gresser; D Fontaine-Brouty-Boyé; C Bourali; M T Thomas
Journal:  Proc Soc Exp Biol Med       Date:  1969-01

5.  Conservatism of the approximation sigma (O-E)2-E in the logrank test for survival data or tumor incidence data.

Authors:  R Peto; M C Pike
Journal:  Biometrics       Date:  1973-09       Impact factor: 2.571

6.  Interferon production by the spleen of rats after intravenous injection of Sindbis virus or heat-killed Escherichia coli.

Authors:  P De Somer; A Billiau
Journal:  Arch Gesamte Virusforsch       Date:  1966

7.  Heterotransplantation of human malignant tumors in "nude" thymusless mice. I. Breeding and maintenance of "nude" mice.

Authors:  B C Giovanella; J S Stehlin
Journal:  J Natl Cancer Inst       Date:  1973-08       Impact factor: 13.506

8.  Interferon in mice: protection against small doses of virus.

Authors:  N B Finter
Journal:  J Gen Virol       Date:  1967-07       Impact factor: 3.891

9.  Effect of interferon, polyacrylin acid, and polymethacrylic acid on tail lesions on mice infected with vaccinia virus.

Authors:  E De Clercq; P De Somer
Journal:  Appl Microbiol       Date:  1968-09

10.  Comparative study of the efficacy of different forms of interferon therapy in the treatment of mice challenged intranassaly with vesicular stomatitis virus (VSV).

Authors:  E De Clercq; P De Somer
Journal:  Proc Soc Exp Biol Med       Date:  1971-10
View more
  14 in total

1.  Cytotoxic T lymphocytes and natural killer cell activity in the course of mengo virus infection of mice.

Authors:  D Hassin; R Fixler; H Bank; A S Klein; Y Hasin
Journal:  Immunology       Date:  1985-12       Impact factor: 7.397

2.  Liver-specific alpha 2 interferon gene expression results in protection from induced hepatitis.

Authors:  L Aurisicchio; P Delmastro; V Salucci; O G Paz; P Rovere; G Ciliberto; N La Monica; F Palombo
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

3.  Scintigraphic study of radiolabelled interferon-alpha in osteosarcoma patients.

Authors:  R A Diez; B Perdereau; M Peter; T Dorval; R Gongora; E T Falcoff
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

Review 4.  The interferon system as a basis for antiviral therapy or prophylaxis.

Authors:  A Billiau
Journal:  Antiviral Res       Date:  1985       Impact factor: 5.970

Review 5.  Interferon therapy: pharmacokinetic and pharmacological aspects.

Authors:  A Billiau
Journal:  Arch Virol       Date:  1981       Impact factor: 2.574

6.  Tissue distribution of human interferons after exogenous administration in rabbits, monkeys, and mice.

Authors:  A Billiau; H Heremans; D Ververken; J van Damme; H Carton; P de Somer
Journal:  Arch Virol       Date:  1981       Impact factor: 2.574

7.  Distribution of mouse interferon-beta in normal and brain tumour-bearing mice.

Authors:  Y Mihara; J Kuratsu; S Takaki; K Hori; E Nagai; Y Satoh; N Minowa; Y Ushio
Journal:  Acta Neurochir (Wien)       Date:  1991       Impact factor: 2.216

8.  Temporal and anatomic relationship between virus replication and cytokine gene expression after vaginal simian immunodeficiency virus infection.

Authors:  Kristina Abel; David M Rocke; Barinderpal Chohan; Linda Fritts; Christopher J Miller
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

9.  Regulated and liver-specific tamarin alpha interferon gene delivery by a helper-dependent adenoviral vector.

Authors:  Luigi Aurisicchio; Amedeo De Tomassi; Nicola La Monica; Gennaro Ciliberto; Cinzia Traboni; Fabio Palombo
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

Review 10.  The potential role of interferons and interferon antagonists in inflammatory disease.

Authors:  H Heremans; A Billiau
Journal:  Drugs       Date:  1989-12       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.